# Rani Therapeutics Holdings, Inc. (RANI)

> Source: Nexqual · https://nexqual.com/RANI · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Rani Therapeutics Holdings, Inc. (RANI), nexqual.com/RANI" · informational, not investment advice.

**Price:** USD 0.68 (+1.46% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.67 · day 0.65–0.69 · 52w 0.61–3.87 · market cap $95.6M · NGM

## Key facts
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 7.2 (range 5–11).
- Total return with dividends: 1Y +44.4% vs S&P 500 +18.1%; 5Y -96.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.05, revenue estimate $1.3M.

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 7.2 (low 5, high 11).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | HC Wainwright & Co. | Reiterated | Buy | $11 |
| 2026-08-18 | Chardan Capital | Initiated | Buy | $6 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +44.4% | -96.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +44.6% | -48.9% |
| Volatility (annualized) | 165.2% | 99.7% |
| Max drawdown | -77.8% (Oct 2025→Jul 2026) | -98.8% (Nov 2021→Jul 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/RANI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt